ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "cytokines and rheumatoid arthritis (RA)"

  • Abstract Number: 720 • 2013 ACR/ARHP Annual Meeting

    Abatacept Efficacy Is Overruled By IL-7 In TSLP-Primed Myeloid Dendritic cell driven T Cell Activation From Rheumatoid Arthritis Patients

    F.M. Moret1, T.R.D.J. Radstake2, J.W.J. Bijlsma1, F.P.J.G. Lafeber3 and J.a.G. van Roon4, 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 3Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, 4Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands

    Background/Purpose: Abatacept is an effective treatment for a subset of rheumatoid arthritis (RA) patients, interfering in the interaction between antigen-presenting cells and T cells preventing…
  • Abstract Number: 1727 • 2013 ACR/ARHP Annual Meeting

    Novel Selective Inhibitors Of Nuclear Export Attenuate Inflammation and Prevent Bone Mineral Density Loss In Multiple Preclinical Models Of Rheumatoid Arthritis

    Mwanasha Hamuza1, Yosef Landesman1, Boris Klebanov1, Michael Kauffman1, Sharon Shacham1, Judith Endres2, David A. Fox3 and Dilara McCauley1, 1Karyopharm Therapeutics Inc., Natick, MA, 2Rheumatology/Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, 3Rheumatology/Int Medicine, University of Michigan Medical Center, Ann Arbor, MI

    Background/Purpose: Exportin 1 (XPO1; also called chromosome region maintenance 1, CRM1) is a key protein that controls the export of ~220 cargo proteins and several…
  • Abstract Number: 1459 • 2013 ACR/ARHP Annual Meeting

    Multiple Cytokine Profiling Predicts The Effectiveness Of Switching Biologics In Rheumatoid Arthritis

    Kensuke Koyama1, Katsunori Ikari1, Atsuo Taniguchi2, Shigeki Momohara2 and Hisashi Yamanaka1, 1Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 2Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose: There is some rheumatoid arthritis (RA) patients with poor responses to certain biologics which requires switching to another biologics. However, there is no solid…
  • Abstract Number: 1388 • 2013 ACR/ARHP Annual Meeting

    Multiplex Cytokine Analyses In Patients With Rheumatoid Arthritis Require Use Of Agents Blocking Heterophilic Antibody Activity

    Peter Olsson1, Elke Theander2, Ulf Bergström3, Stefan Jovinge4, Lennart Jacobsson3 and Carl Turesson2, 1Section of Rheumatology, Department of Clinical Sciences, Lund University, Malmö, Sweden, 2Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 3Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Strategic Research Center for Stem Cell Biology and Cell Therapy, Lund University, Lund, Sweden

    Background/Purpose: Rheumatoid factor (RF) and other circulating heterophilic antibodies have been shown to interfere with antibody-based immunoassays, in particular with multiplex protein detection platforms.  Previous…
  • Abstract Number: 2162 • 2012 ACR/ARHP Annual Meeting

    Correlation of A Multi-Biomarker Disease Activity (VECTRA™ DA) Score with Clinical Disease Activity and Its Components with Radiographic Progression in Rheumatoid Arthritis Patients Treated with Tofacitinib

    Kunihiro Yamaoka1, Satoshi Kubo1, Koshiro Sonomoto1, Shintaro Hirata1, Guy Cavet2, Rebecca Bolce2, Michael W. Rowe2, David Chernoff2, Nadine Defranoux2, Kazuyoshi Saito1 and Yoshiya Tanaka1, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Crescendo Bioscience Inc., South San Francisco, CA

    Background/Purpose: A multi-biomarker disease activity (MBDA) score has been developed for evaluation of disease activity of rheumatoid arthritis (RA) to complement clinical assessment and to…
  • « Previous Page
  • 1
  • 2
  • 3
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology